Frontotemporal Disorders Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Frontotemporal Disorders Treatment market is segmented by Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Others), Disease Indication (Frontotemporal Dementia, Primary Progressive Aphasia, Movement Disorders), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

Market Snapshot

FDT
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Frontotemporal Disorders Treatment market studied is anticipated to grow with a CAGR of nearly 7.2%, during the forecast period.

Certain factors that are driving the market growth include growing prevalence of dementia and other frontotemporal disorders, increasing drug development grants and funding by government as well as non-government organisations.

Increasing prevalence of target disease and growing geriatric population suffering from these diseases are expected to promote the growth of the market. According to the World Health Organization, around 50 million people have dementia, and there are nearly 10 million new cases every year which is anticipated to boost the industry growth.

The increasing government funding for the target disease care, support, and research activities is estimated to fuel the growth of this industry. Various organizations involved in this activity include the National Institute of Health (NIH), Alzheimer’s Association, and National Institute on Aging. In 2019, the NIH has spent around USD 387 million on research projects for Alzheimer's Disease Related Dementias (ADRD). These initiatives are anticipated to provide this market with growth opportunities. However, lack of awareness regarding target disease in developing country may restrict the market.

Scope of the Report

Frontotemporal disorders are forms of dementia caused by a family of brain diseases known as frontotemporal lobar degeneration (FTLD). It majorly involves a severe loss of thinking abilities that interferes with a person's ability to perform daily activities such as working, driving, and preparing meals.

By Drug Class
Cognitive Enhancers
Antipsychotics
Antidepressants
CNS Stimulants
Others
By Disease Indication
Frontotemporal Dementia
Primary Progressive Aphasia
Movement Disorders
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Antidepressants Show Lucrative Opportunity in the Global Frontotemporal Disorders Treatment Market

  • Antidepressant drugs are used for the treatment of major depressive disorders and other conditions, including dysthymia, anxiety disorders, obsessive-compulsive disorder (OCD), eating disorders, chronic pain, neuropathic pain, etc.
  • In October 2018, Lundbeck has launched Brintellix tablets, which are used for the treatment of Major Depressive Disorder in India. Similarly, in April 2019, Lupin has launched antidepressant Fluoxetine tablets in the American market. The tablets are indicated for the treatment of the major depressive disorder, obsessive-compulsive disorder.
  • Thus, owing to the rising number of the patient pool and recent product launches the market is expected to witness high growth across the globe over the forecast period.
22 seg fdt.png

North America Dominates the Global Frontotemporal Disorders Treatment Market

  • North America dominated with revenue estimated as a result of the presence of sophisticated healthcare facilities and infrastructure in developed countries, such as the U.S. High purchasing power for expensive drugs, reimbursement policies and increasing patient pool are the drivers projected to boost the market demand.
  • As per the National Institute of Neurological Disorders and Stroke, Alzheimer’s disease alone, as one dementia disorder, affects more than 5 million people in the U.S. The toll on individuals, caregivers and society is enormous and is expected to increase as the population ages. This aids in supplementing the regional growth.
  • The Asia Pacific is expected to witness the fastest growth over the forecast period owing to the rising disposable income level. In addition, the high prevalence of the target diseases due to the growing geriatric population base coupled with the weak immune system is attributed to the growth of this industry.
geo fdt.png

Competitive Landscape

The Frontotemporal Disorders Treatment market is competitive and consists of a few major players. Companies like Apotex Inc., AstraZeneca plc., Auro Pharma, Johnson & Johnson, Mylan N.V., Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals USA, Inc., among others, hold the substantial market share in the market. And in the coming years, few other players are also expected to enter into the market.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Prevalence of Dementia and Other Frontotemporal Disorders

      2. 4.2.2 Increasing Drug Development Grants and Funding by Government as well as Non-Government Organisations

    3. 4.3 Market Restraints

      1. 4.3.1 Cost Issues and Lack of Awareness across Several Regions

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Cognitive Enhancers

      2. 5.1.2 Antipsychotics

      3. 5.1.3 Antidepressants

      4. 5.1.4 CNS Stimulants

      5. 5.1.5 Others

    2. 5.2 By Disease Indication

      1. 5.2.1 Frontotemporal Dementia

      2. 5.2.2 Primary Progressive Aphasia

      3. 5.2.3 Movement Disorders

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Online Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Apotex Inc.

      2. 6.1.2 AstraZeneca plc.

      3. 6.1.3 Auro Pharma

      4. 6.1.4 Johnson & Johnson

      5. 6.1.5 Mylan N.V.

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 Sanofi S.A.

      8. 6.1.8 Teva Pharmaceuticals USA, Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Frontotemporal Disorders Treatment Market market is studied from 2018 - 2026.

The Frontotemporal Disorders Treatment Market is growing at a CAGR of 7.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Johnson & Johnson , Apotex Inc. , Auro Pharma , Pfizer Inc. , Teva Pharmaceuticals USA, Inc. are the major companies operating in Frontotemporal Disorders Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!